---
title: "Edesa Biotech | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275946604.md"
datetime: "2026-02-13T21:34:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275946604.md)
  - [en](https://longbridge.com/en/news/275946604.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275946604.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275946604.md) | [繁體中文](https://longbridge.com/zh-HK/news/275946604.md)


# Edesa Biotech | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.45.

EBIT: As of FY2026 Q1, the actual value is USD -2.341 M.

#### Financial Results for the Three Months Ended December 31, 2025

-   **Total Operating Expenses**: Increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year .
    -   **Research and Development Expenses**: Increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, compared to $1.0 million for the same period last year .
    -   **General and Administrative Expenses**: Increased by $0.3 million to $1.2 million for the three months ended December 31, 2025, compared to $0.9 million for the same period last year .
-   **Loss from Operations**: -$2,341,383 for the three months ended December 31, 2025, compared to -$1,898,689 for the three months ended December 31, 2024 .
-   **Total Other Income**: Decreased by $0.2 million to $0.1 million for the three months ended December 31, 2025, compared to $0.3 million for the same period last year .
    -   **Reimbursement Grant Income**: $102,425 for the three months ended December 31, 2025, compared to $301,195 for the three months ended December 31, 2024 .
    -   **Other Income (Loss)**: -$8,711 for the three months ended December 31, 2025, compared to -$19,759 for the three months ended December 31, 2024 .
-   **Net Loss**: Edesa Biotech, Inc. reported a net loss of -$2.2 million for the quarter ended December 31, 2025, compared to a net loss of -$1.6 million for the quarter ended December 31, 2024 .
-   **Net Comprehensive Loss**: -$2,252,984 for the three months ended December 31, 2025, compared to -$1,598,597 for the three months ended December 31, 2024 .

#### Working Capital

-   **Cash and Cash Equivalents**: $12.1 million as of December 31, 2025 .
-   **Working Capital**: $12.0 million as of December 31, 2025 .

#### Cash Flows

-   **Net Cash Used in Operating Activities**: -$2,087,334 for the three months ended December 31, 2025, compared to -$1,517,203 for the three months ended December 31, 2024 .
-   **Net Cash Provided by Financing Activities**: $3,355,419 for the three months ended December 31, 2025, compared to $2,071,545 for the three months ended December 31, 2024 .
-   **Cash and Cash Equivalents, End of Period**: $12,051,748 for the three months ended December 31, 2025, compared to $1,563,502 for the three months ended December 31, 2024 .

#### Outlook

Edesa Biotech, Inc. anticipates recruitment for its EB06 Phase 2 vitiligo study to commence midyear 2026, subject to regulatory approvals, with manufacturing plans reported to be on schedule . The company plans to present its Phase 3 respiratory and subgroup data at upcoming scientific and medical conferences and is exploring accelerated commercialization and broader strategic opportunities for paridiprubart . Management expects research expenditures to generally align with EB06 program activities and aims to achieve clinical objectives more efficiently by evaluating opportunities such as establishing investigational sites across multiple jurisdictions .

### Related Stocks

- [Edesa Biotech, Inc. (EDSA.US)](https://longbridge.com/en/quote/EDSA.US.md)

## Related News & Research

- [(TGT) Target Expects Fiscal 2026 Adjusted EPS Range $7.50 to $8.50, vs. FactSet Est of $7.63](https://longbridge.com/en/news/277614261.md)
- [Sysco CFO Stepping Down, Interim CFO Named; Reaffirms Fiscal Q3, 2026 Guidance](https://longbridge.com/en/news/277950666.md)
- [Kosmos Energy beats top-line and bottom-line estimates; introduces Q1 and FY26 outlook](https://longbridge.com/en/news/277424009.md)
- [Ross Stores, Inc. Increases Quarterly Cash Dividend, Payable on March 31, 2026](https://longbridge.com/en/news/277683104.md)
- [Lupin says Visufarma B.V. deal anticipated to complete in April 2026](https://longbridge.com/en/news/277192348.md)